multigram-scale drug production

Acesis BioMed is a Colorado (USA) and London (UK) based biomedical company operating through Acesis Holdings Corporation and its subsidiaries Acesis Biomed US, Inc. and Acesis Biomed Ltd. It develops a platform of oral drug candidates for metabolic and endocrine disorders, initially focusing on male hypogonadism (low T) and related co-morbidities. Its proprietary first-in-class T peptide modulator is designed as a non-steroid alternative to Testosterone Replacement Therapy.

Read more

drug developmentpeptide drug designpreclinical researchR&D via academic centers and CROs